ABIOMED INC. overview

Abiomed (Nasdaq: ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been enrolled in the trial. Amir Kaki, MD, director of mechanical circulatory support at Ascension St. John Hospital in Detroit, led the procedures. This single-arm, prospective, multi-center trial will evaluate the rate of major adverse cardiovascular and cerebrovascular events (MACCE) in...

Abiomed (Nasdaq: ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed’s newest heart pump for patients experiencing right heart failure. All three patients have now been successfully weaned off Impella support and two have already returned home with their native heart. The patients were treated at Hackensack University Medical Center/Hackensack Meridian Health in Hackensack, N.J., and Kingwood Medical Center in Kingwood, Texas....

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Abiomed, Inc. (NasdaqGS: ABMD) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Abiomed will receive $380.00 in cash for each share of Abiomed that they own and a non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and...

INVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of ABIOMED, Inc. - ABMD PR Newswire NEW YORK, Nov. 1, 2022 NEW YORK , Nov. 1, 2022 /PRNewswire/ -- Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City , is investigating ABIOMED, Inc. (...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Abiomed, Inc. (NasdaqGS: ABMD) to Johnson & Johnson (NYSE: JNJ). Under the terms of the proposed transaction, shareholders of Abiomed will receive $380.00 in cash for each share of Abiomed that they own and a non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and...

SHAREHOLDER ALERT: Weiss Law Investigates Abiomed, Inc. PR Newswire NEW YORK, Nov. 1, 2022 NEW YORK , Nov. 1, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Abiomed, Inc. ("Abiomed" or the "Company") (NASDAQ: ABMD), in connection with its proposed tender offer by Johnson & Johnson (NYSE: JNJ). Under the tender offer, the Company's shareholders will receive $380.00 in cash, reflecting an enterprise value...

Thinking about buying stock in Atlas Corp, Unity Biotechnology, Abiomed, Tilray, or Pfizer? PR Newswire NEW YORK, Nov. 1, 2022 NEW YORK , Nov. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATCO, UBX, ABMD, TLRY, and PFE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ATCO:...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ABIOMED, Inc. (NASDAQ: ABMD) to Johnson & Johnson is fair to ABIOMED shareholders. Under the terms of the agreement, ABIOMED shareholders would receive $380.00 per share in cash and a non-tradeable contingent value right entitling the holder to receive up to $35.00 per share in cash if certain commercial and clinical milestones are achieved. Halper Sadeh encourages ABIOMED shareholders to click here to learn more...